Skip to content

The effect of esketamine on the effective dose of cyclopofol for inducing loss of consciousness in pediatric patients.

The effect of esketamine on the effective dose of cyclopofol for inducing loss of consciousness in pediatric patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107036
Enrollment
Unknown
Registered
2025-08-01
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Cyclopofol group :The initial dose of cyclopofol was 0.5mg/kg, and the administration was completed by slow intravenous injection within 30s. The OAA/S score was performed every 30 seconds after the
If a negative indicator occurs, the next child will receive an escalating dose of cranpopol. The study starts with the first two patients with negative reactions and ends when there are 7 positive and
Combination of esketamine and cyclopofol group:Intravenous ketamine 0.5mg/kg plus cyclopofol 0.5mg/kg was used as the starting dose, and the administration was completed by slow intravenous injection

Sponsors

Third Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 4 Years

Inclusion criteria

Inclusion criteria: 1. Children undergoing elective general anesthesia surgery 2. ASA classification I or II; 3. Age range of 1-4 years old; 4. Gender is not limited 5. Body mass index 13-20kg/m2;

Exclusion criteria

Exclusion criteria: 1.Patients with anemia, malnutrition, or significant hepatic/renal dysfunction; 2.Severe cardiovascular diseases; 3.Intellectual disability; 4.Neuropsychiatric disorders; 5.History of hypersensitivity to anesthetic agents; 6.Chronic use of sedative-hypnotic medications within 30 days prior to enrollment.

Design outcomes

Primary

MeasureTime frame
50% effective dose;

Secondary

MeasureTime frame
Mean arterial pressure;Heart rate;Pulse oximetry;Adverse drug reactions during the trial period(hypertension);Adverse drug reactions during the trial period(hypotension);Adverse drug reactions during the trial period(hiccups);Adverse drug reactions during the trial period(cough);Adverse drug reactions during the trial period(nausea and vomiting);Adverse drug reactions during the trial period(logorrhea);Adverse drug reactions during the trial period(body movement);Adverse drug reactions during the trial period(injection Pain);

Countries

China

Contacts

Public ContactZhang Yu

Third Affiliated Hospital of Zhengzhou University

zdsfyzhangyu@163.com+86 371 6690 3862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026